Kyle Todd is the founder and CEO of Zeal Oncology, a global competitive intelligence consultancy focused on cancer therapeutics. Through Zeal Oncology, he serves as a strategic partner to his biotech, pharma, and investor clients.
Kyle leverages his bespoke datasets to discern novelty and realize opportunities even in crowded landscapes/markets. Prior to founding Zeal Oncology, Kyle had spent a decade in drug discovery and early development, most recently at Cytonus Therapeutics.
Kyle holds a BS in Cellular Biology and Molecular Genetics from the University of Maryland and a PhD in Infectious Diseases from the University of Georgia. Based in Carlsbad, California, Kyle enjoys beach volleyball, electronic dance music, and Formula 1.
Veritux independent consultants are available where you need them – in all major markets and every global region.
